Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250

1.

Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age.

Buckley R, Saling MM, Ames D, Rowe CC, Lautenschlager NT, Macaulay SL, Martins RN, Masters CL, O'Meara T, Savage G, Szoeke C, Villemagne VL, Ellis KA; Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL) Research Group.

Int Psychogeriatr. 2013 Aug;25(8):1307-15. doi: 10.1017/S1041610213000665. Epub 2013 May 22.

PMID:
23693133
2.

Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).

Ellis KA, Szoeke C, Bush AI, Darby D, Graham PL, Lautenschlager NT, Macaulay SL, Martins RN, Maruff P, Masters CL, McBride SJ, Pike KE, Rainey-Smith SR, Rembach A, Robertson J, Rowe CC, Savage G, Villemagne VL, Woodward M, Wilson W, Zhang P, Ames D; AIBL Research Group.

Int Psychogeriatr. 2014 Apr;26(4):543-54. doi: 10.1017/S1041610213001956. Epub 2013 Nov 20.

PMID:
24252258
3.

Personal memory function in mild cognitive impairment and subjective memory complaints: results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing.

Buckley RF, Saling MM, Irish M, Ames D, Rowe CC, Lautenschlager NT, Maruff P, Macaulay SL, Martins RN, Masters CL, Rainey-Smith SR, Rembach A, Savage G, Szoeke C, Ellis KA.

J Alzheimers Dis. 2014;40(3):551-61. doi: 10.3233/JAD-131820.

PMID:
24496075
4.

Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.

Lim YY, Ellis KA, Harrington K, Ames D, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Darby D, Maruff P, The Aibl Research Group.

J Clin Exp Neuropsychol. 2012;34(4):345-58. doi: 10.1080/13803395.2011.643227. Epub 2012 Jan 17.

PMID:
22248010
5.

Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease.

Buckley RF, Ellis KA, Ames D, Rowe CC, Lautenschlager NT, Maruff P, Villemagne VL, Macaulay SL, Szoeke C, Martins RN, Masters CL, Savage G, Rainey-Smith SR, Rembach A, Saling MM; Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group.

Neuropsychology. 2015 Jul;29(4):571-81. doi: 10.1037/neu0000156. Epub 2015 Feb 9.

PMID:
25664464
6.

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease.

Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M, Ames D; AIBL Research Group.

Int Psychogeriatr. 2009 Aug;21(4):672-87. doi: 10.1017/S1041610209009405. Epub 2009 May 27.

PMID:
19470201
7.

Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.

Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R, Robins P, Tochon-Danguy H, O'Keefe G, Pike KE, Yates P, Szoeke C, Salvado O, Macaulay SL, O'Meara T, Head R, Cobiac L, Savage G, Martins R, Masters CL, Ames D, Villemagne VL.

Ann Neurol. 2013 Dec;74(6):905-13. doi: 10.1002/ana.24040.

8.

Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.

Foster JK, Albrecht MA, Savage G, Lautenschlager NT, Ellis KA, Maruff P, Szoeke C, Taddei K, Martins R, Masters CL, Ames D; AIBL Research Group.

Brain. 2013 Jul;136(Pt 7):2201-16. doi: 10.1093/brain/awt127. Epub 2013 Jun 3.

9.

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.

Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL.

Neurobiol Aging. 2010 Aug;31(8):1275-83. doi: 10.1016/j.neurobiolaging.2010.04.007. Epub 2010 May 15.

PMID:
20472326
10.

Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.

Lim YY, Ellis KA, Harrington K, Kamer A, Pietrzak RH, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne VL, Ames D, Maruff P.

Neuropsychology. 2013 May;27(3):322-32. doi: 10.1037/a0032321.

PMID:
23688214
11.

Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.

Pike KE, Ellis KA, Villemagne VL, Good N, Chételat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC.

Neuropsychologia. 2011 Jul;49(9):2384-90. doi: 10.1016/j.neuropsychologia.2011.04.012. Epub 2011 Apr 16.

PMID:
21529702
12.

Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: the AIBL Active trial.

Cyarto EV, Lautenschlager NT, Desmond PM, Ames D, Szoeke C, Salvado O, Sharman MJ, Ellis KA, Phal PM, Masters CL, Rowe CC, Martins RN, Cox KL.

BMC Psychiatry. 2012 Oct 11;12:167. doi: 10.1186/1471-244X-12-167.

13.

Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults.

Hollands S, Lim YY, Buckley R, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Lautenschlager N, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P.

J Alzheimers Dis. 2015;43(2):677-86. doi: 10.3233/JAD-140678.

PMID:
25114076
14.

Influence of population versus convenience sampling on sample characteristics in studies of cognitive aging.

Brodaty H, Mothakunnel A, de Vel-Palumbo M, Ames D, Ellis KA, Reppermund S, Kochan NA, Savage G, Trollor JN, Crawford J, Sachdev PS.

Ann Epidemiol. 2014 Jan;24(1):63-71. doi: 10.1016/j.annepidem.2013.10.005. Epub 2013 Oct 12.

PMID:
24211070
15.

Rates of decline distinguish Alzheimer's disease and mild cognitive impairment relative to normal aging: integrating cognition and brain function.

Liddell BJ, Paul RH, Arns M, Gordon N, Kukla M, Rowe D, Cooper N, Moyle J, Williams LM.

J Integr Neurosci. 2007 Mar;6(1):141-74.

PMID:
17472227
16.

Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease.

Julayanont P, Brousseau M, Chertkow H, Phillips N, Nasreddine ZS.

J Am Geriatr Soc. 2014 Apr;62(4):679-84. doi: 10.1111/jgs.12742. Epub 2014 Mar 17.

PMID:
24635004
17.

Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.

Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeke C, Martins RN, Masters CL, Villemagne VL, Rowe CC; AIBL Research Group.

Brain. 2014 Jan;137(Pt 1):221-31. doi: 10.1093/brain/awt286. Epub 2013 Oct 30.

18.

Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) ε4 allele in the elderly: retrospective analysis of data from the CREDOS study.

Son SJ, Lee KS, Lee Y, Baek JH, Choi SH, Na DL, Seo SW, Oh BH, Hong CH.

J Clin Psychiatry. 2012 Dec;73(12):1555-62. doi: 10.4088/JCP.12m07702. Epub 2012 Oct 30.

PMID:
23146133
19.

Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study.

Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, Pertile KK, Rembach A, Rowe CC, Rumble RL, Szoeke C, Taddei K, Taddei T, Trounson BO, Villemagne VL, Ward V, Ames D, Masters CL, Bush AI.

J Alzheimers Dis. 2011;27(4):909-22. doi: 10.3233/JAD-2011-110752.

PMID:
21891867
20.

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.

Mol Psychiatry. 2004 Jul;9(7):705-10.

PMID:
14699432
Items per page

Supplemental Content

Write to the Help Desk